Related Experiment Video
Updated: May 29, 2025

Experimental Model to Evaluate Resolution of Pneumonia
Published on: February 17, 2023
Corticosteroids in community-acquired pneumonia: a step forward, but questions remain
Luis Felipe Reyes1, Ignacio Martin-Loeches2
1Unisabana Center for Translational Science, School of Medicine, Universidad de La Sabana, Chia, Colombia; Pandemic Sciences Institute, University of Oxford, Oxford, UK.
No abstract available in PubMed .
More Related Videos
03:53Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes
Published on: April 19, 2024
09:17A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
Published on: January 2, 2017
Related Concept Videos
COPD: Management Using Bronchodilators and Corticosteroids
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia II: Pathophysiology
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
Pneumonia III: Complications and Assessment
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include: